AU2001257451A1 - Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism - Google Patents

Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism

Info

Publication number
AU2001257451A1
AU2001257451A1 AU2001257451A AU5745101A AU2001257451A1 AU 2001257451 A1 AU2001257451 A1 AU 2001257451A1 AU 2001257451 A AU2001257451 A AU 2001257451A AU 5745101 A AU5745101 A AU 5745101A AU 2001257451 A1 AU2001257451 A1 AU 2001257451A1
Authority
AU
Australia
Prior art keywords
alzheimer
disease
prevention
treatment
medium chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257451A
Other languages
English (en)
Other versions
AU2001257451A8 (en
Inventor
Samuel T. Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerecin Inc
Original Assignee
Accera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22743976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001257451(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Accera Inc filed Critical Accera Inc
Publication of AU2001257451A1 publication Critical patent/AU2001257451A1/en
Publication of AU2001257451A8 publication Critical patent/AU2001257451A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001257451A 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism Abandoned AU2001257451A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20098000P 2000-05-01 2000-05-01
US60/200,980 2000-05-01
PCT/US2001/013955 WO2001082928A1 (en) 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism

Publications (2)

Publication Number Publication Date
AU2001257451A1 true AU2001257451A1 (en) 2001-11-12
AU2001257451A8 AU2001257451A8 (en) 2006-11-09

Family

ID=22743976

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257451A Abandoned AU2001257451A1 (en) 2000-05-01 2001-05-01 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism

Country Status (10)

Country Link
US (3) US20020006959A1 (enExample)
EP (3) EP2319508A1 (enExample)
JP (2) JP2003531857A (enExample)
AT (1) ATE425750T1 (enExample)
AU (1) AU2001257451A1 (enExample)
DE (1) DE60138019D1 (enExample)
DK (1) DK1292294T3 (enExample)
ES (2) ES2752800T3 (enExample)
PT (1) PT1292294E (enExample)
WO (1) WO2001082928A1 (enExample)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
EP2319508A1 (en) 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
EP1605950A4 (en) * 2003-03-06 2008-01-09 Accera Inc NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS
GB0306394D0 (en) 2003-03-20 2003-04-23 Univ Nottingham Carnitine retention
CA2527940C (en) 2003-06-03 2016-03-22 Richard L. Veech Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778615A4 (en) 2004-07-20 2010-01-06 Btg Int Ltd OLIGOMERE KETONE COMPOUNDS
EP1796658B1 (en) * 2004-09-21 2016-03-30 BTG International Limited Dopaminergic mimetics
US7702343B2 (en) * 2005-04-04 2010-04-20 Qualcomm Incorporated Efficient gap allocation for cell measurements in asynchronous communication networks
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
FR2885491B1 (fr) * 2005-05-16 2020-03-06 Nutricos Technologies Traitement de la secheresse keratinique par des glycerides
EP2468273A3 (en) * 2005-06-20 2012-07-11 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
JP2009514965A (ja) * 2005-11-07 2009-04-09 ペーク，エルエルシー 代謝障害を制御するための組成物およびその使用方法
US20100144875A1 (en) * 2005-12-15 2010-06-10 Larson Brian T Compositions and Methods for Preserving Brain Function
HUE035852T2 (en) * 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
ES2579229T3 (es) * 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
FI2144618T4 (fi) 2007-03-28 2025-02-13 Aker Biomarine Antarctic As Biovaikuttavat krilliöljykoostumukset
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
EP2150265A4 (en) * 2007-05-14 2010-06-09 Neuera Pharmaceuticals Inc INHIBITORS OF ACETYL-COA-CARBOXYLASE FOR THE TREATMENT OF NEURONAL HYPOMETABOLISM
WO2009002145A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
WO2009002166A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Improving memory in subjects with mini-mental state examination of 24-26
WO2009002146A1 (en) 2007-06-26 2008-12-31 N.V. Nutricia Supporting activities of daily living
WO2009018478A2 (en) * 2007-07-31 2009-02-05 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
US8282965B2 (en) 2007-12-20 2012-10-09 N.V. Nutricia Liquid nucleotides/nucleosides-containing product
TR201908522T4 (tr) 2008-01-04 2019-07-22 The Government Of The U S A As Represented By The Secretary Dept Of Health And Human Services Kan lipidi düşürücü maddeler olarak keton gövdeleri ve keton gövde esterleri.
KR101734152B1 (ko) 2008-07-03 2017-05-11 액세라인크 신경계 장애의 치료를 위한 아세토아세테이트의 모노글리세리드 및 유도체
US8105809B2 (en) 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
AU2009270697A1 (en) * 2008-07-18 2010-01-21 Dart Neuroscience Llc Methods and systems for evaluating memory agents
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
MX348036B (es) * 2009-12-30 2017-05-24 Baylor Res Institute Terapia anaplerótica para la enfermedad de alzheimer y el cerebro envejecido.
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
CA2847057C (en) 2011-08-31 2019-06-11 St. Jude Children's Research Hospital Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
GB201210699D0 (en) * 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
JP6883384B2 (ja) 2012-11-05 2021-06-09 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 電離放射線による傷害から組織を防護するためのケトン体
MX373650B (es) 2012-12-13 2020-03-31 Baylor Res Institute At Dallas Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1.
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
CA2905225C (en) 2013-03-14 2021-05-04 Isis Innovation Limited Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
WO2014153416A1 (en) 2013-03-19 2014-09-25 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
US9833430B2 (en) 2013-11-14 2017-12-05 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
SG11201606275WA (en) * 2014-02-11 2016-08-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
AU2015358958B2 (en) 2014-12-08 2020-10-01 Société des Produits Nestlé S.A. Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
US10668041B2 (en) 2014-12-08 2020-06-02 Societe Des Produits Nestle Sa Compositions and methods comprising medium chain triglycerides for treatment of epilepsy
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
CN108289873A (zh) * 2015-12-04 2018-07-17 雀巢产品技术援助有限公司 用于改善认知的方法
WO2017093449A1 (en) * 2015-12-04 2017-06-08 Nestec S.A. Medium chain triglyceride compositions
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US10736548B2 (en) * 2016-05-18 2020-08-11 Invoy Holdings, Inc. Ketone measurement system for monitoring medical conditions
KR20190017873A (ko) 2016-06-08 2019-02-20 썬리겐 헬쓰케어 아게 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도
JP7246843B2 (ja) * 2016-08-26 2023-03-28 日油株式会社 スポーツ飲料
KR102306138B1 (ko) 2017-03-15 2021-09-28 세레신 인코포레이티드 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
EP3765002B1 (en) * 2018-03-15 2025-03-05 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US20220125925A1 (en) * 2019-03-04 2022-04-28 Cerecin Inc. Medium chain triglyceride formulations with improved bioavailability and methods related thereto
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
BR112023000185A2 (pt) * 2020-07-23 2023-01-31 Nestle Sa Formulações de tcm para melhorar as funções cognitivas e métodos para produzir e usar tais formulações
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
US20230372276A1 (en) * 2020-10-09 2023-11-23 Cerecin Inc. Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo
CN118340207A (zh) * 2024-05-10 2024-07-16 华中农业大学 一种防治老年痴呆症的食用油脂及其制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2766145A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US2766146A (en) * 1954-07-26 1956-10-09 Reynolds Tobacco Co R Tobacco
US3053677A (en) * 1959-11-12 1962-09-11 Eastman Kodak Co Petroleum wax for paper coatings
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
FR2490631A1 (fr) * 1980-09-24 1982-03-26 Roussel Uclaf Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4528197A (en) 1983-01-26 1985-07-09 Kabivitrum Ab Controlled triglyceride nutrition for hypercatabolic mammals
US4551523A (en) * 1983-04-14 1985-11-05 Eastman Kodak Company Preparation of saccharide acetoacetates
US4847296A (en) 1984-09-13 1989-07-11 Babayan Vigen K Triglyceride preparations for the prevention of catabolism
US5126373A (en) 1987-11-19 1992-06-30 Henri Brunengraber Composition for parenteral and oral nutrition
SE8803141L (sv) 1988-09-07 1990-03-08 Kabivitrum Ab Naeringsmedel foer maenniskor och djur
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
DE3843238C1 (enExample) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
IT1240775B (it) 1990-02-23 1993-12-17 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
AU640010B2 (en) 1990-04-26 1993-08-12 Procter & Gamble Company, The Shortening compositions containing polyol fatty acid polyesters
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
GB9113484D0 (en) 1991-06-21 1991-08-07 Unilever Plc Cosmetic composition
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
AU677614B2 (en) * 1992-10-13 1997-05-01 Duke University Methods of detecting Alzheimer's disease
JP3486778B2 (ja) * 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US5420335A (en) 1993-09-30 1995-05-30 Birkhahn; Ronald H. Parenteral nutrients based on watersoluble glycerol bisacetoacetates
US5438042B1 (en) * 1993-10-08 1997-08-26 Sandoz Nutrition Ltd Enteral nutritional composition having amino acid profile
JP3645580B2 (ja) 1993-10-22 2005-05-11 株式会社フジモト・ブラザーズ グルコースエステル誘導体を含有する脳代謝改善剤
US5691325A (en) 1994-01-14 1997-11-25 Sandyk; Reuven Method for ameliorating age-related disease conditions
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US5607967A (en) 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
EP2327404A1 (en) 1994-11-08 2011-06-01 Avicena Group, Inc. Use of creatine or creatine analogs for the treatment of diseases of the nervous system
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US6319498B1 (en) 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
JP4598203B2 (ja) * 1995-12-01 2010-12-15 ビーティージー・インターナショナル・リミテッド 脳機能改善剤
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
DE19609476A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
IT1284650B1 (it) 1996-05-24 1998-05-21 Sigma Tau Ind Farmaceuti Farmaco a base di un derivato della carnitina per il trattamento della demenza di alzheimer in pazienti ad insorgenza precoce della patologia
KR980008239A (ko) * 1996-07-26 1998-04-30 김충환 사이클로스포린-함유 약학적 조성물
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
RU2224510C2 (ru) * 1997-03-17 2004-02-27 Би Ти Джи Интернэшнл Лимитед Терапевтические композиции
US6316038B1 (en) * 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
AU759467B2 (en) 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
ATE283056T1 (de) 1998-07-22 2004-12-15 Metabolix Inc Nahrungs- und therapeutische verwendung von hydroxyalkanoat oligomere
GB2341389B (en) * 1998-09-14 2000-07-12 Pan Pacific Pharmaceuticals In Useful properties of a bee venom protein and gene encoding same
ES2283133T3 (es) * 1998-09-15 2007-10-16 Btg International Limited Composiciones terapeuticas (ii).
GB9908202D0 (en) 1999-04-12 1999-06-02 Unilever Plc Cosmetic compositions
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
EP2319508A1 (en) 2000-05-01 2011-05-11 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
DE20012857U1 (de) * 2000-07-27 2000-11-09 Sportmedizin Team Vertriebs Gmbh, Berneck Diätetisches Lebensmittel zum Fettabbau
US6667397B2 (en) 2000-08-25 2003-12-23 Eastman Chemical Company Methods of preparing disaccharide and trisaccharide C6-C12 fatty acid esters with high alpha content and materials therefrom
GB2368011A (en) 2000-10-17 2002-04-24 Unilever Plc Fatty acid esters of maltose and uses thereof
US20020103139A1 (en) * 2000-12-01 2002-08-01 M. Weisspapir Solid self-emulsifying controlled release drug delivery system composition for enhanced delivery of water insoluble phytosterols and other hydrophobic natural compounds for body weight and cholestrol level control
KR100479741B1 (ko) 2000-12-30 2005-03-30 주식회사 엘지생활건강 글루코오스 아실화 유도체 또는 수크로오스 아실화유도체를 함유하는 피부미백제
JP2004534050A (ja) * 2001-06-07 2004-11-11 エーザイ株式会社 細胞ストレスに関連する疾病及び状態を予防及び治療する方法
AU2002336759A1 (en) * 2001-09-21 2003-04-14 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
AU2003268235A1 (en) * 2002-09-09 2004-03-29 Mitochroma Research, Inc. Compositions and methods for treating niddm and other conditions and disorders associated with ampk regulation
US6884454B2 (en) 2002-10-21 2005-04-26 Julio Lionel Pimentel Appetite suppressing diet bar
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1605950A4 (en) 2003-03-06 2008-01-09 Accera Inc NOVEL CHEMICAL ENTITIES AND METHODS OF USE IN THE TREATMENT OF METABOLIC DISORDERS
CA2527940C (en) 2003-06-03 2016-03-22 Richard L. Veech Nutritional supplements and therapeutic compositions comprising (r)-3-hydroxybutyrate derivatives
US20050013884A1 (en) * 2003-07-16 2005-01-20 Rennels M. Scott Compositions and methods for treating heart disease
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
US20060252775A1 (en) 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US20100144875A1 (en) 2005-12-15 2010-06-10 Larson Brian T Compositions and Methods for Preserving Brain Function
HUE035852T2 (en) * 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
WO2008005818A1 (en) 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose

Also Published As

Publication number Publication date
ES2752800T3 (es) 2020-04-06
EP1292294A1 (en) 2003-03-19
EP2319508A1 (en) 2011-05-11
JP2012188431A (ja) 2012-10-04
JP5701245B2 (ja) 2015-04-15
DE60138019D1 (de) 2009-04-30
PT1292294E (pt) 2009-06-01
AU2001257451A8 (en) 2006-11-09
JP2003531857A (ja) 2003-10-28
EP2065041B1 (en) 2019-07-31
EP1292294A4 (en) 2004-04-14
WO2001082928A9 (en) 2006-06-15
DK1292294T3 (da) 2009-06-22
EP2065041A1 (en) 2009-06-03
WO2001082928A1 (en) 2001-11-08
ATE425750T1 (de) 2009-04-15
EP1292294B1 (en) 2009-03-18
US20020006959A1 (en) 2002-01-17
US20120196932A1 (en) 2012-08-02
ES2323940T3 (es) 2009-07-28
US8426468B2 (en) 2013-04-23
US20060122270A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
AU2001257451A1 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
WO1998020864A3 (en) Use of selected non-steroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
AU2002357311A1 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
WO2004071431A3 (en) Method and composition for treating neurodegenerative disorders
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
TW264480B (enExample)
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
WO2005004814A3 (en) Sirt1 and genetic disorders
WO2004077938A3 (en) Novel chemical entities and methods for their use in treatment of metabolic disorders
AU6896801A (en) Use of vegf and homologues to treat neuron disorders
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
MY139368A (en) Novel cyclohexyl sulphones
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
CA2200126A1 (en) Treatment and prophylaxis of pancreatitis
AU3866997A (en) Preventive or remedy for alzheimer's disease
BR0314541A (pt) Tratamento de demência e doença de parkinson
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
WO2004028456A3 (en) Method and composition for treating neurodegenerative disorders
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
AU5768298A (en) Use of benzoylalkyl-1,2,3,6-tetrahydropyridins
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT
HK1066571A (en) Compositions and methods for the prevention and treatment of huntington's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase